Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-07-01
Saila:	BMC Cancer
Gaiak:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
Sarrera elektronikoa:	https://doi.org/10.1186/s12885-025-14400-9
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!